AI SummaryThis article discusses how disturbances in the microbiome may impact the onset and severity of Alzheimer’s and Parkinson’s diseases. Research is being conducted to determine if mitigating these disturbances can slow or reverse the progression of these neurodegenerative diseases.Research into these neurodegenerative diseases is exploring how disturbances in our microbiome might influence their onset… Continue reading How Gut Health May Affect Alzheimer’s and Parkinson’s
Tag: Alzheimer’s Disease
Repurposing of USFDA-approved drugs to identify lead for inhibition of acetylcholinesterase enzyme: A plausible utility as an anti-Alzheimer agent
AI SummaryThe article discusses the repurposing of USFDA-approved drugs to identify leads for the inhibition of the acetylcholinesterase enzyme as a potential anti-Alzheimer agent. Through Structure-Based Virtual Screening and in vitro assessments, domperidone was identified as a lead compound with inhibitory effects on AChE. However, due to its poor BBB permeability, new analogues were proposed… Continue reading Repurposing of USFDA-approved drugs to identify lead for inhibition of acetylcholinesterase enzyme: A plausible utility as an anti-Alzheimer agent
Does Multiple Sclerosis Protect Against Alzheimer’s?
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective effect against Alzheimer’s disease. Medscape Medical News
SGLT-2 Inhibitors Reduce Dementia Risk vs DPP-4 Inhibitors
In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing the risk for dementia and Alzheimer’s disease. Medscape Medical News
[ASAP] The Antiproteinopathy, Antioxidant, and Antiapoptotic Effects of Methylene Blue and 4-Phenylbutyric Acid Alone, and in Combination on Familial Alzheimer’s Disease PSEN1 I416T Cholinergic-Like Neurons
Amyloid-{beta} Causes NMDA Receptor Dysfunction and Dendritic Spine Loss through mGluR1 and AKAP150-Anchored Calcineurin Signaling
AI SummaryThis research investigates how amyloid-β affects NMDA receptors and dendritic spine loss, potentially impairing learning and memory in Alzheimer’s disease. The study shows that amyloid-β engages AKAP-CaN signaling through mGluR1 activation, leading to changes in NMDA receptor function and dendritic spine stability. This highlights a new way in which amyloid-β disrupts synaptic function.Neuronal excitatory… Continue reading Amyloid-{beta} Causes NMDA Receptor Dysfunction and Dendritic Spine Loss through mGluR1 and AKAP150-Anchored Calcineurin Signaling
New Diagnostic Criteria for Alzheimer’s Will Change Practice
AI SummaryThis content suggests that new blood biomarker tests for Alzheimer’s disease will change diagnostic criteria, making it more conclusive and less reliant on exclusionary methods. This could potentially improve diagnosis accuracy and help guide treatment decisions.With new blood biomarker tests, Alzheimer’s disease will no longer be just a diagnosis of exclusion. Medscape Family Medicine
[ASAP] Peptide-Based Strategies: Combating Alzheimer’s Amyloid β Aggregation through Ergonomic Design and Fibril Disruption
BiochemistryDOI: 10.1021/acs.biochem.4c00371
Early Testing for Alzheimer’s: What Are The Ethical Costs?
AI SummaryThis article discusses the ethical and financial considerations surrounding early testing for Alzheimer’s disease using blood tests. Ethicist Art Caplan explores the potential costs, both ethical and financial, associated with such tests.Ethicist Art Caplan discusses ethical and financial considerations for new Alzheimer’s detection blood tests. Medscape Business of Medicine
Nighttime Outdoor Light Pollution Linked to Alzheimer’s Risk
A new national study showed the association between AD risk and nighttime light pollution was seen across subgroups, with younger people particularly vulnerable. Medscape Medical News